The Food and Drug Administration has approved a new antibiotic that can treat uncomplicated urinary tract infections, or ...
Key TakeawaysBlujepa (gepotidacin) is the first new antibiotic class approved in nearly 30 years, providing a crucial ...
The US Food and Drug Administration (FDA) has early this week approved GSK's new antibiotic, Blujepa (gepotidacin), for the ...
Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes.
The FDA approved gepotidacin for the treatment of uncomplicated UTIs in women and adolescent girls aged 12 years or older, ...
The FDA approved GSK's Blujepa for uncomplicated UTIs in female adults and pediatric patients, with phase 3 trials showing strong efficacy vs. nitrofurantoin.
Blujepa, which treats UTIs in female patients aged 12 and up with common and uncomplicated infections, will hit the market in ...
The FDA approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new ...
The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...
The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract ...
The FDA approved oral gepotidacin (Blujepa) for uncomplicated urinary tract infections (UTIs) in women and girls ages 12 ...